Lectin, Galactoside-Binding, Soluble, 9 (LGALS9) (Middle Region) Peptid
LGALS9
Reaktivität: Human
Wirt: Synthetic
BP, WB
Produktnummer ABIN5512361
Kurzübersicht für Lectin, Galactoside-Binding, Soluble, 9 (LGALS9) (Middle Region) Peptid (ABIN5512361)
Target
Galectin 9 (LGALS9)
(Lectin, Galactoside-Binding, Soluble, 9 (LGALS9))
Spezies
Human
Quelle
Synthetic
Applikation
Blocking Peptide (BP), Western Blotting (WB)
-
-
Protein Region
- Middle Region
-
Sequenz
- YVVCNTRQNG SWGPEERKTH MPFQKGMPFD LCFLVQSSDF KVMVNGILFV
-
Produktmerkmale
- This is a synthetic peptide designed for use in combination with anti-LGALS9 Antibody. It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
-
-
-
-
Applikationshinweise
- Optimal working dilution should be determined by the investigator.
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Lyophilized
-
Rekonstitution
- Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
-
Lagerung
- -20 °C
-
Informationen zur Lagerung
- For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
-
-
- Galectin 9 (LGALS9) (Lectin, Galactoside-Binding, Soluble, 9 (LGALS9))
-
Hintergrund
-
The galectins are a family of beta-galactoside-binding proteins implicated in modulating cell-cell and cell-matrix interactions. LGALS9 is an S-type lectin. It is overexpressed in Hodgkin's disease tissue and might participate in the interaction between the H&RS cells with their surrounding cells and might thus play a role in the pathogenesis of this disease and/or its associated immunodeficiency.
Protein Size: 323 -
Gen-ID
- 3965
Target
-
Sie sind hier:
